TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04934488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Peer-Delivered 1-Day CBT-Based Workshop
Description: It is a day-long intervention delivered in 4 modules. Each participant is given a professionally designed manual to facilitate learning. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online Peer-Delivered 1-Day CBT-Based Workshop
Description: It is a day-long intervention delivered in 4 modules. Each participant is given a professionally designed manual to facilitate learning. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays.
Study: NCT05150951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Novel Exploration
Description: Exploration of a novel 3D-environment in virtual reality.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Threat conditioning
Description: Session 1. Threat conditioning to two different (CS+, CS-) virtual reality contexts (i.e rooms). One of these is paired with a mild electric shock. The context paired with the electric shock (CS+) is counterbalanced across participants. Participants are instructed that they may receive electrical shocks during the procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Threat conditioning
Description: Session 1. Threat conditioning to two different (CS+, CS-) virtual reality contexts (i.e rooms). One of these is paired with a mild electric shock. The context paired with the electric shock (CS+) is counterbalanced across participants. Participants are instructed that they may receive electrical shocks during the procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extinction
Description: Session 2. Participants are repeatedly exposed to the both contexts from session 1 (CS+, CS-), but no shocks are delivered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extinction
Description: Session 2. Participants are repeatedly exposed to the both contexts from session 1 (CS+, CS-), but no shocks are delivered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinstatement
Description: Session 3. Participants are again repeatedly exposed to both contexts from session 1 (CS+, CS-), after a few shocks delivered in a neutral context.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinstatement
Description: Session 3. Participants are again repeatedly exposed to both contexts from session 1 (CS+, CS-), after a few shocks delivered in a neutral context.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual attention control task
Description: Session 2. A visual attention task used as a control task instead of novel exploration.
Study: NCT06327932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TURBT
Description: Transurethral Resection of Bladder Tumors

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TURBT
Description: Transurethral Resection of Bladder Tumors

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIVEC
Description: Hyperthermic Intravesical Chemotherapy with Gemcitabine (3g/150ml NS) at 45 °C for 60 minutes. Induction perfusion was required to start within 4 weeks, once a week (±5 days) for 6 to 8 times. After the last induction infusion, maintenance infusion was performed, once every month (±2 weeks) for 1 year from the first induction infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical Chemotherapy
Description: Intravesical Chemotherapy with Gemcitabine (3g/150ml NS). Induction perfusion was required to start within 4 weeks, once a week (±5 days) for 6 to 8 times. After the last induction infusion, maintenance infusion was performed, once every month (±2 weeks) for 1 year from the first induction infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (3g/150ml NS).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine (3g/150ml NS).
Study: NCT05205915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS intervention applied by Starstim device
Description: Stimulation will be applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents). The montage has been designed to optimize anodal stimulation in the desired target area while avoiding stimulation off target.
Study: NCT05029479

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bonding in NCCLs
Description: bonding agent which can resist moisture and has shorter decalcifying and curing time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bonding in NCCLs
Description: bonding agent which can resist moisture and has shorter decalcifying and curing time
Study: NCT05419895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Diagnostic Response Model (EDRM)
Description: Use of telehealth capabilities to implement measures and capture and code information related to an autism diagnosis. This program evaluation will be using pre- and post-data and data collected through the process to evaluate the effectiveness of the EDRM pilot.
Study: NCT06104462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Description: The iTBS protocol consists of 20 trains of stimulation. Each train comprises ten 3-pulse bursts, delivered at an intra-burst frequency of 50 Hz, with a 5 Hz overall frequency, followed by 8 seconds of rest. A total of 600 pulses (10\*3\*20) will be administered in this 3-minute iTBS protocol. Concurrent TBS/fNIRS stimulation will be applied over the left DLPFC at an intensity of 90% of the resting motor threshold (RMT), which is considered appropriate to ensure compliance and elicit robust DLPFC activation.~Considering that the fNIRS optode beneath the coil increases the distance between the TMS coil and the skull by 10 mm, we will use the equation AdjMT% = MT + 2.8 \* (Dsitex - Dm1). Therefore, 2.8 \* 10 = 28% will be added to the normal intensity. The stimulation site over the DLPFC will be determined by the MNI coordinate (x-38, y+44, z+26) reported in previous studies.
Study: NCT05223920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Capsule (oral)
Study: NCT06565949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education group
Description: aregivers in the experimental group will be given a detailed and planned training programme on pressure sores. The trainings will be held in a total of four sessions, with twenty minutes in each session, two weeks apart.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: In the first stage of the study, the participants in the experimental and control groups were asked to complete the 'Introductory Information Form' and '' Pressure sore knowledge test' will be completed. In the second stage of the research, no intervention will be made to the caregivers in the control group, and in the last stage of the research, 'Pressure sore knowledge test' will be filled in as post-test data for all participants.
Study: NCT06340802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNS Treatment
Description: Vagus nerve stimulation is started 2-week after the implantation
Study: NCT05174416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Mavacamten Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching PBO capsules during placebo controlled period，and mavacamten capsules during long term extension period
Study: NCT05320549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Programme
Description: Participants have the opportunity to engage in face-to-face and/or online exercise classes. Attendance will be recorded.
Study: NCT05169320

Intervention type: DEVICE
Intervention: Subcutaneous implantable loop recorder (ILR) implantation
Description: All patients will undergo subcutaneous implantable loop recorder (ILR) implantation to quantify AF burden 1 month before the ablation procedure and at least 1 year after the ablation procedure.

Intervention type: PROCEDURE
Intervention: Mapping and catheter ablation
Description: Driver regions will be identified during persistent AF using a conventional electroanatomical mapping system, multielectrode mapping catheters, and leading-driver maps generated by novel single-signal algorithms based on an automatic and accurate analysis of the instantaneous amplitude and frequency modulations displayed by atrial signals (iAM and iFM, respectively). Such maps enable the location of the spatiotemporally stable regions that drive persistent AF (leading drivers). Leading-driver regions that can be reasonably targeted/isolated with catheter ablation without high-risk of complications upon radiofrequency delivery will be targeted for ablation.

Intervention type: PROCEDURE
Intervention: Minimally invasive surgical ablation via thoracoscopy
Description: This procedure will be performed only in those patients whose leading-driver maps in the previous mapping and catheter ablation procedure fulfill the following requirements:~1. Extensive atrial remodeling who will not likely get any benefit from catheter-based ablation due to too large atrial leading driver areas (≥10-15% of atrial surface), or~2. Leading drivers located at regions with high-risk of complications upon radiofrequency delivery (e.g. left and right atrial appendages, coronary sinus, in the vicinity \[≤5 mm\] of the cardiac specific conduction system).~In such patients, the leading-driver regions not completely targeted or not targeted at all in the previous index mapping and catheter ablation procedure, will be specifically ablated/isolated by minimally invasive surgical ablation techniques via thoracoscopy.
Study: NCT05810337

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Splenda drink
Description: 4.5g Splenda containing 1% sucralose, 95% maltodextrin, dissolved in 250ml water and consumed with a high carbohydrate breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin drink
Description: 4.5g maltodextrin dissolved in 250ml water and consumed with a high carbohydrate breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High carbohydrate breakfast
Description: Meal consisting of 30g cereal with 100ml skimmed milk, 1.5 slices white toast with 12g margarine, providing 386kcal, 61.4g carbohydrate, 10.4g protein and 10.1g fat.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High carbohydrate breakfast
Description: Meal consisting of 30g cereal with 100ml skimmed milk, 1.5 slices white toast with 12g margarine, providing 386kcal, 61.4g carbohydrate, 10.4g protein and 10.1g fat.
Study: NCT04778956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); Toripalimab should be completed for 2 cycles at 1-2 weeks before surgery, and continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: salvage surgery
Description: Endoscopic nasopharyngectomy is used for recurrent nasopharyngeal tumor and selective neck dissection for recurrent regional lymph node.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: salvage surgery
Description: Endoscopic nasopharyngectomy is used for recurrent nasopharyngeal tumor and selective neck dissection for recurrent regional lymph node.
Study: NCT05782426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel polymeric micelles for injection
Description: Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles. If patient assessment is of clinical benefit, maintenance therapy with sindilizumab plus paclitaxel polymeric micelles for injection(≤230mg/m\^2) can be continued based on investor's evaluation and patient's own choice until disease progression (PD), unacceptable toxicity, withdrawal of consent, initiation of additional antineoplastic therapy, death, or other protocol-specified conditions for discontinuation of treatment, whichever comes first.
Study: NCT06071026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Net Ultra Filtration Rate
Description: The net ultra filtration rate is modified every 6 hours accordingly to randomisation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Net Ultra Filtration Rate
Description: The net ultra filtration rate is modified every 6 hours accordingly to randomisation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Net Ultra Filtration Rate
Description: The net ultra filtration rate is modified every 6 hours accordingly to randomisation
Study: NCT06294132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Manipulation
Description: The participant lies on the right side. The right leg is straightened at the knee. The left knee is flexed to the level to be manipulated, and the left foot is placed behind the right lower leg. The caregiver introduces rotation of the participant's upper body down to the level to be manipulated. The caregiver then takes up an axillary hold. The caregiver places his right forearm in the region between the gluteus medius and maximus. The caregiver then rolls the participant towards them. Prior to thrusting, the caregiver applies a slight overpressure and holds the position for 10 seconds. If the participant does not experience any adverse effects, over-pressure is released, and the restrictive barrier re=engaged. The caregiver applies a HVLA thrust against the participant's buttocks by dropping their body. If a cavitation pop is not heard the first time, a second attempt is made. The procedure is repeated on the opposite side.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Lumbar Manipulation
Description: The participant lies on the right side. The right leg is straightened at the knee. The left knee is flexed SLIGHTLY, and the left foot is placed behind the right lower leg. The caregiver DOES NOT introduce rotation of the participant's upper body down to the level to be manipulated. The caregiver then takes up an axillary hold. The caregiver places his right forearm in the region between the gluteus medius and maximus. The caregiver DOES NOT roll the participant towards them. Prior to thrusting, the caregiver applies a slight overpressure and holds the position for 10 seconds. If the participant does not experience any adverse effects, over-pressure is released, and the restrictive barrier re=engaged. The caregiver applies a HVLA thrust against the participant's buttocks by dropping their body. NO ROTATION OCCURS IN THE SPINE. The procedure is repeated on the opposite side.
Study: NCT05268874

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clavipectoral block
Description: Clavipectoral block will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third (or on the proximal or distal end, according to the localization of the fracture) of the clavicle. A 22-gauge, 50 mm block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 30 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
Study: NCT05363462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin 1000 MG
Description: Application of vancomycin in powder in the surgical site of treatment before closure of surgical wound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin 1000 MG
Description: Application of vancomycin in powder in the surgical site of treatment before closure of surgical wound
Study: NCT05760391

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: IMRT or SABR for patients with ESCC.
Study: NCT05379582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implement nutrition therapy according a procedure assisted by gastrointestinal ultrasound
Description: Once the critical ill patients is stable, enteral nutrition was initiated following a procedure assisted by gastrointestinal ultrasound.
Study: NCT05735821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giving breastfeeding training
Description: The control group will not be interfered with. Breastfeeding training will be given to the video and simulator group and the 3 groups will be compared.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giving breastfeeding training
Description: The control group will not be interfered with. Breastfeeding training will be given to the video and simulator group and the 3 groups will be compared.
Study: NCT04961723

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (OraQuick® HCV Self-Test
Description: The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (OraQuick® HCV Self-Test
Description: The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (OraQuick® HCV Self-Test
Description: The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
Study: NCT04007185

Intervention type: PROCEDURE
Intervention: Maximal, safe resection of brain tumour
Description: Standard surgical resection as part of routine care
Study: NCT04466826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Headache Journal
Description: Phase 1 of study to determine a baseline for headache frequency, headache intensity and medication usage patterns

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Block
Description: Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tx360
Description: Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device
Study: NCT05242185

Intervention type: OTHER
Intervention: Observational study
Description: - Baseline data of prognostic importance, including demographic, social information, lifestyle factors, medical history, underlying comorbidities, anthropometric measurements, clinical, laboratory, imaging and treatment records will be collected using a standard case report form. A detailed clinical examination including measurement of vital signs, blood pressure, pulse oximetry, anthropometric measurements, neurological, pulmonary, cardiovascular system examination, mental and fuctional status assessment. routine laboratory assays including complete blood count (CBC), serum alanine transaminase (ALT), serum creatinine, fasting capillary blood glucose using glucometer and urine routine examination, ECG, echocardiography, chest X-ray and pulmonary function test. Additional tests when required such as fasting blood sugar, glycated haemoglobin, MRI/CT scan of brain, Thyroid function tests such as FT4, FT3 and TSH and C peptide etc
Study: NCT05273853

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Partial Adenoidectomy
Description: Partial removal of adenoid
Study: NCT06521398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doula Support
Description: Doula support including care coordination to mental and medical health services in the NICU, with a warm handoff to a community doula to continue the support once infants leave the HUP NICU.
Study: NCT05559749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: collaborative care
Description: a 24-week neurology based collaborative care program consisting of: 1. a series of every 2 weeks care management calls by the care manager to evaluate anxiety, depression, seizures and side effects and deliver brief therapy interventions to the participant, and 2. collaborative care conferences including a psychiatrist to generate expert recommendations for anxiety and depression management and communication of recommendations between the care manger, psychiatrist and neurologist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual neurology care
Description: ongoing usual neurology care, without the addition of the collaborative care program
Study: NCT06428591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 insulin pump with Tandem Freedom Algorithm
Description: Participants will use the Tandem Freedom system for 3 day/nights in a supervised hotel setting, performing meal and exercise challenges.